CN103142549B - Mannose ester enteric capsule and preparation method thereof - Google Patents
Mannose ester enteric capsule and preparation method thereof Download PDFInfo
- Publication number
- CN103142549B CN103142549B CN201310093191.6A CN201310093191A CN103142549B CN 103142549 B CN103142549 B CN 103142549B CN 201310093191 A CN201310093191 A CN 201310093191A CN 103142549 B CN103142549 B CN 103142549B
- Authority
- CN
- China
- Prior art keywords
- mannose ester
- enteric
- mannose
- ester
- enteric coated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention discloses a mannose ester enteric capsule and a preparation method of the mannose ester enteric capsule. The mannose ester enteric capsule is prepared by placing mannose ester enteric micropelets into a capsule shell, wherein the mannose ester enteric micropelets are composed of mannose ester micropelets and enteric coatings, wherein the enteric coatings are wrapped outside the mannose ester micropelets; the mannose ester micropelets consist of mannose esters and fillers; the enteric coatings are composed of enteric materials, plasticizers and antisticking agents; and when in preparation, the enteric coatings are wrapped outside the mannose ester micropelets so as to obtain the mannose ester enteric capsule. The mannose ester enteric capsule is convenient to take and ideal in enteric effect, and can improve the bioavailability; in addition, the preparation process is simple, the obtained product is stable in quality, and massive production and application can be realized.
Description
Technical field
The present invention relates to a kind of Western medicine preparation technical field, relate in particular to a kind of mannose ester enteric coated capsule, the invention still further relates to the preparation method of this enteric coated capsule.
Background technology
The novel heparinoid class of the one marine drug of mannose ester (PGMS) is the sodium sulfate salt that occupies mannuronic acid propyl ester that propylene glycol alginate sodium sulfate forms through hydrolysis, esterification.Mannose ester, containing a large amount of acidic-groups, belongs to the acid polysaccharide of line style polyanion, and the monosaccharide in structure is only mannuronic acid, has antithrombotic, anticoagulant, arteriosclerosis, enhancing fibrinolytic function, regulates the effects such as blood fat.Mannose ester crude drug and tablet thereof in 1994 through national drug approved by management, produced so far by Qingdao No. 3 Pharmaceutical Factory, mannose ester in the market only has a kind of dosage form of tablet, dosage form dullness, common, be subject to the impact of the factor such as disintegrate, drug release, absorb, therapeutic effect is unsatisfactory, bioavailability is not high.
Enteric coated preparation refers to and do not discharge under one's belt at the appointed time or discharge hardly medicine, and enters in intestinal, can be most of in a part of intestinal or all discharge the preparation of medicine, and enteric coated capsule belongs to the one of enteric coated preparation.Enteric coated preparation can avoid medicine to be subject to the destruction of gastric enzyme or gastric acid, avoids medicine to produce intense stimulus to gastric mucosa, and delayed release effect is provided, and by being mainly passed to this position with maximum concentration as far as possible by the medicine of intestinal absorption, has improved bioavailability.
Summary of the invention
In order to overcome the deficiencies in the prior art, the present invention to adjuvant screening and process optimization, provides a kind of mannose ester enteric coated capsule by lot of experiments.This enteric coated capsule steady quality, medicine discharges in intestinal, and bioavailability is high, and preparation technology is simple.
For achieving the above object, the technical scheme that the present invention takes is:
A kind of mannose ester enteric coated capsule, incapsulate in shell and make by mannose ester enteric coated micropill, described mannose ester enteric coated micropill is made up of mannose ester micropill and the enteric coat layer being wrapped in outside mannose ester micropill, described mannose ester micropill comprises mannose ester and filler, described enteric coat layer comprises enteric material, plasticizer and antiplastering aid, it is characterized in that: note by ratio of weight and the number of copies, the consumption of each composition is:
Preferably, note by ratio of weight and the number of copies, the consumption of each composition is:
Wherein, described filler is microcrystalline Cellulose; Described enteric material is selected from least one in cellulose acetate-phthalate, succinic acid cellulose acetate and Hydroxypropyl Methylcellulose Phathalate; Described plasticizer is glycerol; Described antiplastering aid is micropowder silica gel.
Wherein, described enteric material is preferably cellulose acetate-phthalate and succinic acid cellulose acetate; Most preferably, the weight ratio of cellulose acetate-phthalate and succinic acid cellulose acetate is 3:1.
Mannose ester enteric coated capsule of the present invention can be prepared as follows:
(1) get mannose ester and mix homogeneously with filler, take 85% ethanol as binding agent, make 20～30 object mannose ester micropills, for subsequent use;
(2) with 80% dissolve with ethanol enteric material, plasticizer, antiplastering aid, make enteric coating liquid;
(3) enteric coating liquid preparing is evenly sprayed to the mannose ester micropill surface that step (1) prepares, after being dried, obtains mannose ester enteric coated micropill.
(4) mannose ester enteric coated micropill is packed in capsule shells, obtains final product.
The mannose ester enteric coated capsule the present invention relates to has following beneficial effect:
(1) steady quality, enteric is satisfactory for result, can improve bioavailability;
(2) selected adjuvant is common, and preparation technology is simple, and products obtained therefrom steady quality is applicable to large-scale production and application.
The specific embodiment
Below in conjunction with embodiment, the specific embodiment of the present invention is further described, advantage and disadvantage of the present invention will be more clear along with description.But these embodiment are only exemplary, scope of the present invention are not formed to any restriction.It will be understood by those skilled in the art that lower without departing from the spirit and scope of the present invention and can the details of technical solution of the present invention and form be modified or be replaced, but these modifications and replacement all fall within the scope of protection of the present invention.
A preparation method for mannose ester enteric coated capsule, comprises the following steps:
(1) get mannose ester and mix homogeneously with filler, take 85% ethanol as binding agent, make 20～30 object mannose ester micropills, for subsequent use;
(2) with 80% dissolve with ethanol enteric material, plasticizer, antiplastering aid, make enteric coating liquid;
(3) enteric coating liquid preparing is evenly sprayed to the mannose ester micropill surface that step (1) prepares, after being dried, obtains mannose ester enteric coated micropill.
(4) mannose ester enteric coated micropill is packed in capsule shells, obtains final product.
The preparation of embodiment 1～6 mannose ester enteric coated capsule
The supplementary material of according to the form below, by above-mentioned preparation method, makes the mannose ester enteric coated capsule of six embodiment.Wherein, "/" representative is not used.
The dissolution determination of test example 1 embodiment 1～6 gained mannose ester enteric coated capsule
According to dissolution method (60 page of second method of Chinese Pharmacopoeia two appendix of version in 2000), precision takes appropriate mannose ester enteric coated micropill, dissolution medium is respectively: pH1.2 simulated gastric fluid and pH6.8 simulated intestinal fluid, respectively take simulated gastric fluid and simulated intestinal fluid as solvent, measure dissolution.The results are shown in Table 1 and table 2.
Table 1 embodiment 1～6 mannose ester enteric coated capsule dissolution investigation table in simulated gastric fluid
| ? | 30min | 1h | 2h | 3h | 4h |
| Embodiment 1 | 7.1% | 8.4% | 9.5% | 10.2% | 11.6% |
| Embodiment 2 | 7.9% | 8.8% | 9.7% | 11.2% | 12.8 |
| Embodiment 3 | 8.2% | 9.3% | 10.4% | 11.4% | 12.7% |
| Embodiment 4 | 5.8% | 6.7% | 7.8% | 9.0% | 10.3% |
| Embodiment 5 | 6.7% | 8.9% | 10.0% | 11.2% | 12.5% |
| Embodiment 6 | 7.3% | 8.7% | 9.8% | 10.5% | 11.6% |
As can be seen from Table 1, the stripping in pH1.2 simulated gastric fluid of the prepared mannose ester enteric coated capsule of embodiment 1～6 is slow, 4h stripping is the highest only 12.8%, there is good acid resistance, wherein the mannose ester enteric coated capsule 4h stripping of embodiment 4 is minimum, illustrates that the mannose ester enteric coated capsule acid resistance that uses cellulose acetate-phthalate and succinic acid cellulose acetate to make as the enteric material of coating is best.
Table 2 embodiment 1～6 mannose ester enteric coated capsule dissolution investigation table in simulated intestinal fluid
| ? | 5min | 10min | 15min | 20min | 30min | 40min | 50min | 60min |
| Embodiment 1 | 16.4% | 46.3% | 62.5% | 73.6% | 80.3% | 83.6% | 85.1% | 87.2% |
| Embodiment 2 | 17.4% | 50.9% | 66.3% | 77.8% | 82.4% | 86.2% | 88.2% | 89.0% |
| Embodiment 3 | 15.6% | 43.8% | 58.9% | 70.0% | 76.3% | 80.3% | 84.7% | 87.3% |
| Embodiment 4 | 18.9% | 57.8% | 70.2% | 80.8% | 85.4% | 88.9% | 90.1% | 91.2% |
| Embodiment 5 | 16.5% | 48.9% | 64.6% | 74.5% | 79.8% | 82.2% | 83.5% | 84.7% |
| Embodiment 6 | 15.4% | 42.8% | 56.8% | 68.9% | 75.3% | 78.9% | 82.0% | 85.6% |
As can be seen from Table 2, the prepared mannose ester enteric coated capsule of embodiment 1～6 discharges rapidly in pH6.8 simulated intestinal fluid, can reach the object of rapid release, wherein mannose ester enteric coated capsule dissolution in 60min of embodiment 4 is the highest, illustrates that the mannose ester enteric coated capsule rapid release effect in intestinal that uses cellulose acetate-phthalate and succinic acid cellulose acetate to make as the enteric material of coating is best.
The preparation of embodiment 7～13 mannose ester enteric coated capsulees
The supplementary material of according to the form below, by above-mentioned preparation method, each embodiment makes respectively mannose ester enteric coated capsule.The weight ratio of the cellulose acetate-phthalate of embodiment 7 and succinic acid cellulose acetate is 4:1, the weight ratio of the cellulose acetate-phthalate of embodiment 8 and succinic acid cellulose acetate is 3:1, the weight ratio of the cellulose acetate-phthalate of embodiment 9 and succinic acid cellulose acetate is 2:1, the weight ratio of the cellulose acetate-phthalate of embodiment 10 and succinic acid cellulose acetate is 1:1, the weight ratio of the cellulose acetate-phthalate of embodiment 11 and succinic acid cellulose acetate is 1:2, the weight ratio of the cellulose acetate-phthalate of embodiment 12 and succinic acid cellulose acetate is 1:3, the weight ratio of the cellulose acetate-phthalate of embodiment 13 and succinic acid cellulose acetate is 1:4.
The mannose ester enteric coated capsule dissolution determination of test example 2 embodiment 7～13 gained
Assay method is with test example 1.Measurement result is in table 3 and table 4.
Table 3 embodiment 7～13 mannose ester enteric coated capsulees dissolution investigation table in simulated gastric fluid
| ? | 30min | 1h | 2h | 3h | 4h |
| Embodiment 7 | 6.7% | 7.9% | 8.5% | 9.3% | 10.2% |
| Embodiment 8 | 4.5% | 5.8% | 6.6% | 7.4% | 8.5% |
| Embodiment 9 | 5.2% | 6.9% | 8.0% | 8.8% | 9.8% |
| Embodiment 10 | 5.8% | 6.7% | 7.8% | 9.0% | 10.3% |
| Embodiment 11 | 6.3% | 7.5% | 8.7% | 9.3% | 9.9% |
| Embodiment 12 | 6.4% | 7.7% | 8.9% | 9.8% | 10.5% |
| Embodiment 13 | 7.0% | 8.1% | 9.0% | 9.8% | 10.7% |
As known from Table 3, the stripping in pH1.2 simulated gastric fluid of the prepared mannose ester enteric coated capsule of embodiment 8 is the slowest, when the weight ratio that enteric material cellulose acetate-phthalate and succinic acid cellulose acetate be described is 3:1, prepared mannose ester enteric coated capsule acid resistance is best.
Table 4 embodiment 7～13 mannose ester enteric coated capsulees dissolution investigation table in simulated intestinal fluid
| ? | 5min | 10min | 15min | 20min | 30min | 40min | 50min | 60min |
| Embodiment 7 | 18.5% | 47.8% | 62.1% | 73.6% | 78.8% | 83.4% | 86.7% | 92.0% |
| Embodiment 8 | 19.9% | 59.8% | 73.4% | 82.7% | 87.3% | 90.3% | 92.5% | 94.8% |
| Embodiment 9 | 18.3% | 52.5% | 67.7% | 77.8% | 83.6% | 86.2% | 88.9% | 90.3% |
| Embodiment 10 | 18.9% | 57.8% | 70.2% | 80.8% | 85.4% | 88.9% | 90.1% | 91.2% |
| Embodiment 11 | 17.5% | 48.8% | 62.7% | 73.4% | 80.0% | 84.5% | 86.4% | 89.2% |
| Embodiment 12 | 16.8% | 45.3% | 60.9% | 70.9% | 76.7% | 81.3% | 85.5% | 88.3% |
| Embodiment 13 | 16.0% | 44.4% | 58.5% | 69.8% | 74.2% | 79.9% | 84.7% | 88.9% |
As known from Table 3, the prepared mannose ester enteric coated capsule of embodiment 8 discharges rapidly in pH6.8 simulated intestinal fluid, in 60min, dissolution is the highest, when the weight ratio that enteric material cellulose acetate-phthalate and succinic acid cellulose acetate be described is 3:1, prepared mannose ester enteric coated capsule rapid release effect in intestinal is best.
In sum, known when using adjacent cellulose acetate-phthalate and succinic acid cellulose acetate as enteric material, and both weight ratios are while being 3:1, prepared mannose ester enteric coated capsule acid resistance in gastric juice is good, in intestinal juice, stripping is rapid, and dissolution is high, and effect is best.
Claims (2)
1. a mannose ester enteric coated capsule, incapsulate in shell and make by mannose ester enteric coated micropill, described mannose ester enteric coated micropill is made up of mannose ester micropill and the enteric coat layer being wrapped in outside mannose ester micropill, described mannose ester micropill comprises mannose ester and microcrystalline Cellulose, described enteric coat layer comprises enteric material, glycerol and micropowder silica gel, it is characterized in that: meter by ratio of weight and the number of copies, the consumption of each composition is:
2. the method for preparation mannose ester enteric coated capsule claimed in claim 1, comprises the following steps:
(1) get mannose ester and mix homogeneously with microcrystalline Cellulose, take 85% ethanol as binding agent, make 20～30 object mannose ester micropills, for subsequent use;
(2) with 80% dissolve with ethanol enteric material, glycerol, micropowder silica gel, make enteric coating liquid;
(3) enteric coating liquid preparing is evenly sprayed to the mannose ester micropill surface that step (1) prepares, after being dried, obtains mannose ester enteric coated micropill;
(4) mannose ester enteric coated micropill is packed in capsule shells, obtains final product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310093191.6A CN103142549B (en) | 2013-03-21 | 2013-03-21 | Mannose ester enteric capsule and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310093191.6A CN103142549B (en) | 2013-03-21 | 2013-03-21 | Mannose ester enteric capsule and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103142549A CN103142549A (en) | 2013-06-12 |
| CN103142549B true CN103142549B (en) | 2014-07-02 |
Family
ID=48541065
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310093191.6A Active CN103142549B (en) | 2013-03-21 | 2013-03-21 | Mannose ester enteric capsule and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103142549B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106137977B (en) * | 2015-04-28 | 2019-12-13 | 浙江普利药业有限公司 | Sea cucumber polysaccharide enteric-coated pellet and preparation method thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102743409B (en) * | 2012-06-18 | 2013-11-20 | 中国海洋大学 | Application of poly mannuronic acid propyl ester sulfate in preparing anti- H1N1 influenza A virus medication |
-
2013
- 2013-03-21 CN CN201310093191.6A patent/CN103142549B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN103142549A (en) | 2013-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101987091B (en) | Venlafaxine hydrochloride sustained-release pellet capsules | |
| CN103142539B (en) | Alginic sodium diester controlled-release tablet and preparation method thereof | |
| CN105581992A (en) | Preparation method and application of starch/ferulic acid colon-targeted controlled-release carrier matrix tablet | |
| CN104000796A (en) | Coating auxiliary materials, preparation method and coating method for Chinese herb extract preparations | |
| CN105030723B (en) | A kind of starch capsule and preparation method thereof | |
| CN103142538B (en) | PGMS (Propylene Glycol Mannate Sulfate) enteric tablet and preparation method thereof | |
| CN103142549B (en) | Mannose ester enteric capsule and preparation method thereof | |
| CN103142540B (en) | PGMS (Propylene Glycol Mannate Sulfate) controlled-release tablet and preparation method thereof | |
| CN103142535B (en) | Alginic sodium diester enteric tablet and preparation method thereof | |
| CN106074440B (en) | A kind of capsule and preparation method thereof | |
| CN103127030B (en) | Propylene glycol alginate sodium sulfate enteric capsule and preparation method thereof | |
| CN103142504B (en) | PGMS (Propylene Glycol Mannate Sulfate) sustained-release granule and preparation method thereof | |
| CN103142557B (en) | Polymannuronate sulfate slow release capsule and preparation method thereof | |
| CN103099796B (en) | Propylene glycol marinate sulfate-containing sustained-release preparation and preparation method thereof | |
| CN103142556B (en) | Polysaccharide sulfate sustained-release capsule and preparation method thereof | |
| CN103127004B (en) | Propylene glycol alginate sodium sulfate controlled-release granule and preparation method thereof | |
| CN105193766A (en) | Preparation method of vitamin E soft capsules with good stability | |
| CN103156853B (en) | Paracetamol and caffeine enteric capsule and preparation method thereof | |
| CN103142606B (en) | Paracetamol and caffeine enteric tablet and preparation method thereof | |
| CN100525774C (en) | DiAo Xinxuekang soft capsule and preparation process and use thereof | |
| CN103156849B (en) | Compound pseudoephedrine hydrochloride enteric-coated tablet and preparation method thereof | |
| CN103156852B (en) | Paracetamol, pseudoephedrine hydrochloride, dextromethorphan hydrobromide and chlorpheniramine maleate enteric capsule and preparation method thereof | |
| CN103655645A (en) | Chinese buckeye seed extract tablets and preparation method thereof | |
| CN103156854B (en) | Paracetamol and caffeine slow-release particles and preparation method thereof | |
| CN105395519B (en) | A kind of Topiroxostat spansule and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: 266103 Qingdao economic and Technological Development Zone, unity Road, No. 3601, Shandong Applicant after: Qingdao Zhengda Haier Pharmaceutical Co., Ltd. Address before: 266103 Haier Road, Shandong, Qingdao, No. 1 Applicant before: Qingdao Zhengda Haier Pharmaceutical Co., Ltd. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP01 | Change in the name or title of a patent holder | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 266103 3601 Tuen Jie Road, Qingdao economic and Technological Development Zone, Shandong Patentee after: Zhengda Pharmaceutical (Qingdao) Co., Ltd. Address before: 266103 3601 Tuen Jie Road, Qingdao economic and Technological Development Zone, Shandong Patentee before: Qingdao Zhengda Haier Pharmaceutical Co., Ltd. |